Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Comparison of donepezil, galantamine, rivastigmine, and memantine in vascular dementia
IRCT20181210041912N1Phase 2Completed
- Sponsor
- Kerman University of Medical Sciences
- Start
- Dec 2018
- Modality
- Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, double-blind trial of rivastigmine, donepezil, galantamine and memantine in vascular dementia (4 arms), sponsored by Kerman University of Medical Sciences. Primary endpoints: Mean flow velocity of anterior cerebral artery, Mean flow velocity of middle cerebral artery and 1 more. Started Dec 2018; status: completed.
02
Drugs
rivastigminedonepezilgalantaminememantine
03
Conditions
vascular dementia
Beyond the preview
Go deeper on IRCT20181210041912N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20181210041912N1.